Heather Gardner to Dog Diseases
This is a "connection" page, showing publications Heather Gardner has written about Dog Diseases.
Connection Strength
3.605
-
Gardner HL, Fenger JM, Roberts RD, London CA. Characterizing the metabolic role of STAT3 in canine osteosarcoma. Vet Comp Oncol. 2022 Dec; 20(4):817-824.
Score: 0.751
-
Gardner HL, Rippy SB, Bear MD, Cronin KL, Heeb H, Burr H, Cannon CM, Penmetsa KV, Viswanadha S, Vakkalanka S, London CA. Phase I/II evaluation of RV1001, a novel PI3Kd inhibitor, in spontaneous canine lymphoma. PLoS One. 2018; 13(4):e0195357.
Score: 0.561
-
Gardner HL, Fenger JM, London CA. Dogs as a Model for Cancer. Annu Rev Anim Biosci. 2016; 4:199-222.
Score: 0.473
-
Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res. 2015 Jun 11; 11:131.
Score: 0.460
-
van der Heiden AD, Pensch R, Agger S, Gardner HL, Hendricks W, Zismann V, Wong S, Briones N, Turner B, Forsberg-Nilsson K, London C, Lindblad-Toh K, Arendt ML. Characterization of the genomic landscape of canine diffuse large B-cell lymphoma reveals recurrent H3K27M mutations linked to progression-free survival. Sci Rep. 2025 Feb 08; 15(1):4724.
Score: 0.225
-
McLinden GP, Avery AC, Gardner HL, Hughes K, Rodday AM, Liang K, London CA. Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. J Vet Intern Med. 2024 May-Jun; 38(3):1666-1674.
Score: 0.213
-
London CA, Gardner H, Zhao S, Knapp DW, Utturkar SM, Duval DL, Chambers MR, Ostrander E, Trent JM, Kuffel G. Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology. Vet Comp Oncol. 2023 Dec; 21(4):565-577.
Score: 0.204
-
Barrett LE, Gardner HL, Barber LG, Sadowski A, London CA. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. BMC Vet Res. 2019 Aug 13; 15(1):291.
Score: 0.154
-
Schuh EM, Portela R, Gardner HL, Schoen C, London CA. Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res. 2017 Oct 02; 13(1):294.
Score: 0.135
-
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clin Cancer Res. 2017 May 15; 23(10):2565-2574.
Score: 0.127
-
Randall VD, Boston SE, Gardner HL, Griffin L, Oblak ML, Kubicek L. Pubectomy and stereotactic radiotherapy for the treatment of a non-resectable sacral osteosarcoma causing pelvic canal obstruction in a dog. Can Vet J. 2016 Sep; 57(9):945-9.
Score: 0.125
-
Karrasch NM, Lerche P, Aarnes TK, Gardner HL, London CA. The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. Can Vet J. 2015 Aug; 56(8):817-22.
Score: 0.116
-
Rippy SB, Gardner HL, Nguyen SM, Warry EE, Portela RA, Drost WT, Hostnik ET, Green EM, Chew DJ, Peng J, London CA. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Vet Res. 2016 Nov 17; 12(1):257.
Score: 0.032
-
London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS One. 2015; 10(4):e0124889.
Score: 0.029